VRTX News - Candlesense

Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase

VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that its field crews have...

Operations

about 24 hours ago

Vertex to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Inves...

Investor events

7 days ago

Read more businesswire

The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District

NEWTON, Mass.--(BUSINESS WIRE)--The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgag...

How might this financing affect investor sentiment toward biotech‑focused real‑estate investment trusts? What is the expected impact on earnings per share for both companies under the new financing terms? How does the weighted‑average rate of 5.5957% compare to the companies’ existing debt costs?

Financing

20 days ago

Read more businesswire

Vertex Reports Second Quarter 2025 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 f...

Is there any insider trading activity or large institutional buying/selling around the earnings release? What regulatory or reimbursement risks could affect the commercial performance of the new products? How might the Q2 results affect analyst earnings forecasts and target price revisions?

Earnings

23 days ago

Read more businesswire

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ra...

How might the market’s perception of Vertex’s R&D capabilities change after this disclosure? What are the implications for Vertex's overall pipeline valuation given this setback? Could the results lead to a strategic partnership, licensing deal, or asset divestiture for Vertex?

Clinical trials

23 days ago

Read more businesswire